

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT IMPORTANT COOPERATION AGREEMENT

This announcement is made by the board of directors (the “**Board**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that, the Company and Mayo Foundation for Medical Education and Research (“**Mayo**”) has recently entered into a cooperation agreement (the “**Agreement**”), pursuant to which, Mayo agreed to provide consulting services on organizational objectives and clinical practices to the Group (the “**Cooperation**”). The term of the Agreement is three (3) years.

The Board wishes to emphasize that the implementation of the Cooperation forms the basis for the long-term cooperation between the parties thereto, such Cooperation is subject to the execution of definitive statement(s) of work. Under the statement of work for the first year from the execution date, the cooperation will focus on the improvement on the planning and clinical service capability for clinical disciplines of the Group’s hospital projects.

The Board considers that the Agreement has been entered into on normal commercial terms after arm’s length negotiation between the Company and Mayo, and such cooperation is in the interests of the Company and its shareholders as a whole.

REASONS FOR AND BENEFITS OF ENTERING INTO THE COOPERATION AGREEMENT

The Group intends to improve administrative efficiencies and effectiveness to enhance medical practice and patient care through the implementation of advice from Mayo. At the same time, the Company will work with Mayo to leverage its global expertise in healthcare and practices in the China market. In addition, the Cooperation serves as an opportunity to enhance communications between local and international medical experts.

INFORMATION OF THE PARTIES

The Company is a joint stock company with limited liability incorporated under the laws of the PRC, with its H Shares listed on the Stock Exchange on January 9, 2024. The Company is an oncology healthcare service provider in China serving both cancer patients through its self-owned medical institutions and third-party medical institutions through its medical equipment, software and related services.

Mayo is a private American academic medical center, primarily engaging in the operation of an integrated delivery healthcare system, which consists of various acute care hospitals and medical facilities, and the provision of operational consulting services.

To the best of the Company's directors' knowledge, information and belief, Mayo and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

LISTING RULES IMPLICATION

As at the date of this announcement, entering into the Agreement and the transactions contemplated thereunder do not constitute notifiable transactions or connected transactions under Listing Rules.

The Company will keep the its shareholders and potential investors of the Company informed of any further update in relation to the above by further announcement(s) made by the Company as and when appropriate in compliance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Concord Healthcare Group Co., Ltd.
美中嘉和醫學技術發展集團股份有限公司
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, January 2, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.